Pharmaceutical composition for treating and preventing cardiovascular and cerebrovascular diseases
A technology for cardiovascular and cerebrovascular diseases and compositions, applied in the field of pharmaceutical compositions for treating and preventing cardiovascular and cerebrovascular diseases, and pharmaceutical compositions for relaxing cardiovascular and cerebrovascular smooth muscles
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
experiment example 1
[0037] Experimental Example 1 The relaxing effect of the pharmaceutical composition of the present invention on the aortic vessels of mice
[0038] The mice were 100 male Kunming mice over 3 weeks old, purchased from the Institute of Experimental Animals, Chinese Academy of Medical Sciences. Use granular formulations to feed mice, 2 times a day, 2 mg samples each time, 20 mice fed the pharmaceutical composition were tested on 20, 40, 60, 80, and 100 days, and 20 mice were used as a blank control . The result is figure 1 Shown. The relaxation rate is determined by rapidly removing the thoracic aorta after killing the mouse, peeling off the surface fat and part of the connective tissue, cutting into a 4mm aortic vascular ring, and placing the sample in 10ml Krebs solution (Krebs The liquid contains parts by weight of NaCl 119.0, KCl 4.7, and CaCl 2 2.5, KH 2 PO 4 1.2, MgSO 4 1.2, NaHCO 3 25.0 and glucose 10.0 and water 1000). During the experiment, the pH was stabilized at 7....
experiment example 2
[0039] Experimental Example 2 The effect of the pharmaceutical composition of the present invention on the cardiovascular system of white rabbits.
[0040] Methods: Japanese big-eared white rabbits (purchased from Xi'an Di Lepu Biological Resources Development Co., Ltd., specification 2010-003, were divided into sample group and control group. The sample group was given a liquid dosage form and intravenously administered 12 mg / kg sample. From the rabbit Take blood from the middle ear artery to determine the plasma cGMP content and various indexes of hemorheology
[0041] Results: a. Changes in plasma cGMP content
[0042] After taking the sample at 12 mg / kg, the plasma cGMP content increased significantly, reaching a peak in 2 hours. The detection method is the same as Experimental Example 1, and the results are shown in Table 1.
[0043] b. Changes in blood viscosity
[0044] After taking the sample, the whole blood viscosity decreased significantly, and the decrease was the most sig...
Embodiment 2
[0064] Example 2 illustrates that the pharmaceutical composition of the present invention can be used to improve the content of cGMP, regulate vasodilation, reduce blood viscosity and reduce platelet aggregation, and can be used to treat or prevent vasospasm-related diseases and atherosclerosis-related diseases .
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com